Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: For the treatment of liver fibrosis, several novel cell therapies have been proposed. Autologous macrophage therapy has been reported as one of the promising treatments. So far, most studies have used colony-stimulating factor 1 (CSF-1) to induce the differentiation of macrophage progenitor cells. The receptor for CSF-1, CSF-1R possesses another ligand, interleukin 34. However, the therapeutic capacity for liver fibrosis by interleukin 34-induced macrophages has not been evaluated. Methods: We have employed acute (bile duct ligation) and chronic (administration of carbon tetrachloride or thioacetamide) liver fibrosis models. Using these models, we evaluated the therapeutic capacity of macrophages induced by interleukin 34-based conditions. In most experiments, interleukin 4 was also added to the differentiation process to induce alternative-activated macrophages. As a mechanism analysis, we have examined liver inflammation and damage, the status of stellate cells, and the immunosuppressive capacity of the macrophages. Human macrophages were differentiated from CD14+ monocytes and analyzed. Results: In both acute and chronic liver damage experiments, interleukin 34-induced macrophages significantly ameliorated liver fibrosis. The addition of interleukin 4 to the differentiation process resulted in an increase of obtained macrophages and a bias to alternative activated macrophages (so-called M2). The alternative activated macrophages (M2-type) showed a reproducible therapeutic effect of liver fibrosis with a suppression of parameters of liver inflammation and damage, stellate cells, and T cell activation. Similar macrophages could be differentiated from human CD14+ monocytes in the presence of interleukin 34 plus interleukin 4, and a therapeutic effect was observed using a humanized mouse model. Conclusions: Interleukin 34-induced macrophages, particularly when additionally stimulated with interleukin 4, significantly ameliorated the liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, in liver fibrosis mouse models, infusion of bone marrow-derived macrophages (BMDMs) or macrophages induced by IL-34-conditioned culture mitigated fibrosis by increasing collagen degradation and inducing HSC apoptosis, among other mechanisms (72, 73).”
From Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics (2026) · cites this paper as [73]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous preclinical studies have shown that macrophage therapy can reduce carbon tetrachloride–induced liver fibrosis (47–50) or promote the repair of acute liver injury repair (44, 51).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Junqueira, L. C. U., Bignolas, G., & Brentani, R. R. (1979) · The Histochemical Journal · doi:10.1007/bf01002772 · Cited by 2,574
Klinge, U., Park, J.-K., & Klosterhalfen, B. (2013) · Pathobiology · doi:10.1159/000348446 · Cited by 1,783
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Type 2 immunity in tissue repair and fibrosis
Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055
Wang, Y., Szretter, K. J., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., Barrow, A. D., Diamond, M. S., & Colonna, M. (2012) · Nature Immunology · doi:10.1038/ni.2360 · Cited by 1,011
CSF-1 receptor signaling in myeloid cells.
Stanley, E. R., & Chitu, V. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021857 · Cited by 825
Macrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Cited by
Shi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv2106 · Cited by 30
New perspectives in the treatment of liver cirrhosis: targeting macrophage regulatory mechanisms
Zheng, S., Li, S., Wang, Q., Zao, X., Li, X., Qi, W., Cheng, F., Yuexiao, G. E. N. G., Zhang, P., Shi, X., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07239-y · Cited by 6
“Studies have shown that inducing the polarization of M2-type macrophages helps slow the progression of fibrosis and improves liver function in liver fibrosis models [18, 19].”
Role of IL ‐34 in Tumors and Its Application to Regulate Inflammation
Igarashi, Y., & Seino, K.-I. (2025) · Cancer Science · doi:10.1111/cas.70020 · Cited by 4
Self-citationChen, L., Chen, Y., Zhao, M., Yang, X., Sutte, K., Lu, M., Chen, J., Zheng, X., Yang, D., & Liu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1814879 · Cited by 1
Intestinal reengineering: Scientific advances in intestinal transplantation
Rong, Y., Nie, C.-Y., Zhou, J.-D., Wang, Z., Wu, D. W., Wu, S.-W., & Xie, Z. (2025) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v17.i10.111672 · Cited by 1
“Targeting macrophage polarization is another promising avenue: Colony-stimulating factor-1 receptor inhibitors selectively deplete profibrotic M2 macrophages and attenuate intestinal fibrosis in experimental models[196,197].”
Metadata
- Authors
- Igarashi, Y., Wada, H., Muto, M., Sone, R., Hasegawa, Y., & Seino, K.-I.
- Affiliations
- Hokkaido University (JP)
- Medinet Co., Ltd. (Japan) (JP)
- Kazusa DNA Research Institute (JP)
- Corresponding author
- Seino, Ken-ichiro
- Venue
- Inflammation and Regeneration
- Published
- 2025-01-24
- Volume
- 45
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- PMC
- PMC11758727
- OpenAlex
- W4406807889
- Cited by
- 5
- References
- 30
- Citations by year
- 2026: 1 · 2025: 4
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Inflammation and Regeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- AMED (JP24fk0210117)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- liver fibrosis, IL-34, IL-4, alternative activated macrophages, M2 macrophages, macrophage differentiation, CD14+ monocytes, hepatic stellate cells, liver inflammation, T cell activation, bile duct ligation, carbon tetrachloride, thioacetamide, humanized mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition. https://app.cochat.ai/papers/10.1186/s41232-025-00364-7
- The paper
- Igarashi, Y., Wada, H., Muto, M., Sone, R., Hasegawa, Y., & Seino, K.-I. (2025). Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition. Inflammation and Regeneration. https://doi.org/10.1186/s41232-025-00364-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.